Progyny partners with Oura for women’s health monitoring

NEW YORK - Progyny, Inc. (NASDAQ:PGNY), a provider of women’s health and family building solutions with a market capitalization of $2.04 billion and "GREAT" financial health according to InvestingPro, announced Thursday a partnership with Oura, maker of smart rings that track health metrics. The company’s stock has shown strong momentum, delivering a 37.86% return year-to-date.

The collaboration aims to integrate data from Oura Ring devices into Progyny’s care team process, allowing members to monitor various health metrics including sleep patterns, cycle insights, cardiovascular health, and stress levels.

According to the press release, the partnership is designed to help women better understand their bodies through data collection, which can assist with identifying potential health risks earlier and supporting specific health goals such as conception planning or managing menopause symptoms.

"The more women understand about their bodies, the more empowered they are to partner with their health providers and articulate their health status and goals," said Janet Choi, Progyny’s Chief Medical Officer, in the company statement.

For women trying to conceive, the technology could help identify fertile windows, while those experiencing perimenopause or menopause might use the data to recognize patterns and guide lifestyle adjustments.

Dorothy Kilroy, Chief Commercial Officer at Oura, stated that the partnership aims to "bridge the gap between daily health patterns and clinical care," potentially enabling "smarter care, earlier interventions, and more personalized journeys."

The Oura Ring and membership will become available to Progyny clients, including employers and health plans, starting in early 2026.

Progyny, headquartered in New York City, is listed on the Nasdaq under the ticker PGNY.

In other recent news, Progyny has announced that its second-quarter financial results are expected to surpass the guidance provided in May, driven by favorable member activity. The company had initially projected revenue between $310.0 million and $325.0 million, with expected EBITDA ranging from $49.0 million to $53.0 million. This positive outlook has been supported by analyst firms such as BofA Securities and BTIG, both of which reiterated their Buy ratings and maintained a $30.00 price target for Progyny. Additionally, Progyny has secured a new $200 million revolving credit facility, maturing on July 1, 2030, which remains undrawn and is intended to enhance the company’s financial flexibility.

In other developments, Leerink Partners upgraded Progyny’s stock rating from Market Perform to Outperform, citing improved membership activity and stable utilization trends. The firm views the company’s guidance as conservative, suggesting potential upside for 2025. Furthermore, Progyny is expanding its women’s health services to include pelvic floor therapy, partnering with Origin and Hinge Health to provide both in-person and virtual care options. This expansion aims to address pelvic floor disorders, which affect a significant number of women and can lead to various health complications if untreated. These recent developments reflect Progyny’s ongoing efforts to enhance its service offerings and financial standing.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.